SCHEMBL971942

SCHEMBL971942

Cc1c(Cc2ccccc2)c(=O)oc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
HSD17B3 P37058 4/20 1.00
GAA P10253 4/20 1.00
GLA P06280 2/20 1.00
ERAP1 Q9NZ08 2/20 1.00
NPSR1 Q6W5P4 1/20 1.00
ESR1 P03372 1/20 0.67
AR P10275 1/20 0.67
ALDH1A1 P00352 8/20 0.67
MAPT P10636 3/20 0.67
HPGD P15428 3/20 0.64
TSHR P16473 1/20 0.64
CASP1 P29466 1/20 0.64
CASP7 P55210 1/20 0.64
HSD17B10 Q99714 1/20 0.64
KMT2A Q03164 3/20 0.64
ALDH1A2 O94788 1/20 0.63
ALDH1B1 P30837 1/20 0.63
ALDH1A3 P47895 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15931623 0.88 HSD17B3 (0.79) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL28646880 0.88 HSD17B3 (0.79) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL14246785 0.87 HSD17B3 (0.77) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL5647264 0.87 HSD17B3 (0.77) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL1590671 0.87 HSD17B3 (0.77) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL959893 0.86 KDM4E (0.76) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL14317882 0.86 HSD17B3 (0.76) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL14315176 0.85 HSD17B3 (0.74) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL7797770 0.85 KDM4E (0.74) KDM4EHSD17B3GAAGLAERAP1
SCHEMBL13391475 0.85 HSD17B3 (0.73) KDM4EHSD17B3GAAGLAERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
US-7994318-B2 Coumarin derivatives useful as TNFα inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-08-09 US disclosed
US-7872142-B2 Coumarin derivatives useful as TNFα inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-01-18 US disclosed
US-20100197917-A1 COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-08-05 US disclosed
US-20100174076-A1 COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-08 US disclosed
US-20060020138-A1 Coumarin derivatives useful as TNFalpha inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-01-26 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
US-20050014705-A1 Coumarin derivatives useful as tnf alpha inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-01-20 US disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2002008217-A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014705-A1 Coumarin derivatives useful as tnf alpha inhibitors TNF, NFKBIA, TNFRSF1A KDM4E 4511/4885HSD17B3 1415/4885GAA 659/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL KDM4E 3457/4885HSD17B3 56/4885GAA 21/4885
US-20100197917-A1 COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS TNF, NFKBIA, TNFRSF1A KDM4E 4508/4885HSD17B3 1342/4885GAA 572/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL KDM4E 3778/4885HSD17B3 33/4885GAA 26/4885
US-20100174076-A1 COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS TNF, NFKBIA, TNFRSF1A KDM4E 4508/4885HSD17B3 1342/4885GAA 572/4885
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 KDM4E 4656/4885HSD17B3 3885/4885GAA 970/4885
US-20060020138-A1 Coumarin derivatives useful as TNFalpha inhibitors TNF, NFKBIA, TNFRSF1A KDM4E 4567/4885HSD17B3 1596/4885GAA 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.